We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00111189
First Posted: May 18, 2005
Last Update Posted: June 20, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Janssen-Cilag International NV
Information provided by (Responsible Party):
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.